Morgan Stanley analyst Terence Flynn maintained a Hold rating on C4 Therapeutics (CCCC – Research Report) today and set a price target of ...

On Monday, C4 Therapeutics Inc (CCCC) stock saw a modest uptick, ending the day at $6.45 which represents a slight increase of $0.84 or 14.97% from the prior close of $5.61. The stock opened at $5.58 ...

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 12.50% and 158.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. ( (CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its ...

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 12%. Looking ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported ...

Detailed price information for C4 Therapeutics Inc (CCCC-Q) from The Globe and Mail including charting and trades.

Oct. 31, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported financial ...

WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...

Shares of CCCC opened at $5.30 on Friday. C4 Therapeutics has a 52-week low of $1.06 and a 52-week high of $11.88. The firm has a market cap of $364.67 million, a price-to-earnings ratio of -2.24 ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...